Biennial price revisions will result in pharmaceutical price cuts in Japan this month but the world’s second largest pharmaceutical market still holds great opportunity for global pharma, according to latest analysis from Datamonitor Healthcare.
Anantharaman Kavassery Viswanathan, analyst at Datamonitor Healthcare, said: “In this latest round of cuts the market expansion rule will impact 11 active ingredients (APIs) and 22 products which mostly include big-selling DPP-4 inhibitor...
To continue reading this story Click Here
RECOMMENDED
Upcoming Events
DigIT Pharma AI Commercial Excellence & Health 2025
September 1 - 3 2025
Palace Hotel Berlin, Germany
Register Now |
View Agenda |
Learn More
GenAI Life Science & Health 2025
September 1 - 3 2025
Berlin, Germany
Register Now |
View Agenda |
Learn More